These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 24991835)

  • 1. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
    Mahalingam D; Mita M; Sarantopoulos J; Wood L; Amaravadi RK; Davis LE; Mita AC; Curiel TJ; Espitia CM; Nawrocki ST; Giles FJ; Carew JS
    Autophagy; 2014 Aug; 10(8):1403-14. PubMed ID: 24991835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.
    Patel S; Hurez V; Nawrocki ST; Goros M; Michalek J; Sarantopoulos J; Curiel T; Mahalingam D
    Oncotarget; 2016 Sep; 7(37):59087-59097. PubMed ID: 27463016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
    Rangwala R; Leone R; Chang YC; Fecher LA; Schuchter LM; Kramer A; Tan KS; Heitjan DF; Rodgers G; Gallagher M; Piao S; Troxel AB; Evans TL; DeMichele AM; Nathanson KL; O'Dwyer PJ; Kaiser J; Pontiggia L; Davis LE; Amaravadi RK
    Autophagy; 2014 Aug; 10(8):1369-79. PubMed ID: 24991839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
    Rangwala R; Chang YC; Hu J; Algazy KM; Evans TL; Fecher LA; Schuchter LM; Torigian DA; Panosian JT; Troxel AB; Tan KS; Heitjan DF; DeMichele AM; Vaughn DJ; Redlinger M; Alavi A; Kaiser J; Pontiggia L; Davis LE; O'Dwyer PJ; Amaravadi RK
    Autophagy; 2014 Aug; 10(8):1391-402. PubMed ID: 24991838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
    Rosenfeld MR; Ye X; Supko JG; Desideri S; Grossman SA; Brem S; Mikkelson T; Wang D; Chang YC; Hu J; McAfee Q; Fisher J; Troxel AB; Piao S; Heitjan DF; Tan KS; Pontiggia L; O'Dwyer PJ; Davis LE; Amaravadi RK
    Autophagy; 2014 Aug; 10(8):1359-68. PubMed ID: 24991840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.
    Park H; Garrido-Laguna I; Naing A; Fu S; Falchook GS; Piha-Paul SA; Wheler JJ; Hong DS; Tsimberidou AM; Subbiah V; Zinner RG; Kaseb AO; Patel S; Fanale MA; Velez-Bravo VM; Meric-Bernstam F; Kurzrock R; Janku F
    Oncotarget; 2016 Oct; 7(41):67521-67531. PubMed ID: 27589687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors.
    Brunetto AT; Ang JE; Lal R; Olmos D; Molife LR; Kristeleit R; Parker A; Casamayor I; Olaleye M; Mais A; Hauns B; Strobel V; Hentsch B; de Bono JS
    Clin Cancer Res; 2013 Oct; 19(19):5494-504. PubMed ID: 24065624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC).
    Arora SP; Tenner L; Sarantopoulos J; Morris J; Liu Q; Mendez JA; Curiel T; Michalek J; Mahalingam D
    Br J Cancer; 2022 Oct; 127(6):1153-1161. PubMed ID: 35739299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
    Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
    Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
    Munster PN; Marchion D; Thomas S; Egorin M; Minton S; Springett G; Lee JH; Simon G; Chiappori A; Sullivan D; Daud A
    Br J Cancer; 2009 Oct; 101(7):1044-50. PubMed ID: 19738609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
    Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
    Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors.
    Mehnert JM; Kaveney AD; Malhotra J; Spencer K; Portal D; Goodin S; Tan AR; Aisner J; Moss RA; Lin H; Bertino JR; Gibbon D; Doyle LA; White EP; Stein MN
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):899-907. PubMed ID: 31463691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.
    Pili R; Liu G; Chintala S; Verheul H; Rehman S; Attwood K; Lodge MA; Wahl R; Martin JI; Miles KM; Paesante S; Adelaiye R; Godoy A; King S; Zwiebel J; Carducci MA
    Br J Cancer; 2017 Mar; 116(7):874-883. PubMed ID: 28222071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
    Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM
    Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
    Ramalingam SS; Parise RA; Ramanathan RK; Lagattuta TF; Musguire LA; Stoller RG; Potter DM; Argiris AE; Zwiebel JA; Egorin MJ; Belani CP
    Clin Cancer Res; 2007 Jun; 13(12):3605-10. PubMed ID: 17510206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.
    Wada H; Tsuboi R; Kato Y; Sugaya M; Tobinai K; Hamada T; Shimamoto T; Noguchi K; Iwatsuki K
    J Dermatol; 2012 Oct; 39(10):823-8. PubMed ID: 22506596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.
    Munster PN; Thurn KT; Thomas S; Raha P; Lacevic M; Miller A; Melisko M; Ismail-Khan R; Rugo H; Moasser M; Minton SE
    Br J Cancer; 2011 Jun; 104(12):1828-35. PubMed ID: 21559012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
    Ree AH; Dueland S; Folkvord S; Hole KH; Seierstad T; Johansen M; Abrahamsen TW; Flatmark K
    Lancet Oncol; 2010 May; 11(5):459-64. PubMed ID: 20378407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma.
    Barnard RA; Wittenburg LA; Amaravadi RK; Gustafson DL; Thorburn A; Thamm DH
    Autophagy; 2014 Aug; 10(8):1415-25. PubMed ID: 24991836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort.
    Chi KH; Ko HL; Yang KL; Lee CY; Chi MS; Kao SJ
    Oncotarget; 2015 Jun; 6(18):16735-45. PubMed ID: 25944689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.